Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label AFQ056 in adult patients with Fragile X syndrome
2011-001952-12Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mavoglurant in Fragile X syndrome (FXS), sponsored by Novartis. Primary endpoints: Safety and tolerability of AFQ056 and Efficacy in fully methylated and partially methylated FXS patients. Started Aug 2011; status: completed.
02
Drugs
mavoglurant
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on 2011-001952-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001952-12.